Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its review on Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians and invites the public to submit recommendations for key stakeholders in these categories. None of these individuals or organizations are responsible for the final contents of ICER’s report or should be assumed to support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit ICER’s website.

- Aetna
- Allergy and Asthma Network
- American Academy of Allergy Asthma and Immunology (AAAAI)
- American College of Allergy, Asthma, and Immunology (ACAAI)
- American Lung Association
- American Thoracic Society (ATS)
- Anthem Blue Cross and Blue Shield
- Asthma and Allergy Foundation of America (AAFA)
- Asthma and Allergy Foundation of America - St Louis (AAFA – STL)
- Asthma Ready Communities (ARC)
- AstraZeneca
- Chicago Asthma Consortium (CAC)
- Express Scripts Holding Company
- Genentech/Novartis
- GlaxoSmithKline plc
- National Heart, Lung, and Blood Institute (NHLBI)
- Respiratory Health Association
- Sanofi Genzyme/Regeneron
- Severe Asthma Foundation
- Teva Pharmaceutical Industries Ltd.